GGrantIndex
← Leaderboards

Murray Korc

University Of California Irvine

$11,956,061
Attributed
$11,956,061
Total exposure
8
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.3M · FY200522
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22

Funding mix

By agency

NIH$12,195,911 · 9

By mechanism

R01$8,858,316 · 4
R37$2,201,455 · 1
R21$778,314 · 2
P20$239,850 · 1
P30$117,976 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of California Irvine

Same institution · by research overlap

Others in their field

Top investigators on “Tumor

Research focus

TumorCancer CellMalignant Neoplasm Of PancreasCellsMalignant NeoplasmsBaseMouse ModelSignal TransductionBiologicalNeoplasm MetastasisPancreatic Ductal AdenocarcinomaApoptosisCell LinePancreasIncidenceIn VitroMolecularGrowthMutateMediatingSignal PathwayProtein IsoformsOverexpressionGrowth Factor Receptors

Grant awards (47)

Tumor Microenvironment and Metastasis Program$29,494
P30 · FY2022 · CA · contact PI
Tumor Microenvironment and Metastasis Program$29,494
P30 · FY2021 · CA · contact PI
Tumor Microenvironment and Metastasis Program$29,494
P30 · FY2020 · CA · contact PI
Tumor Microenvironment and Metastasis Program$29,494
P30 · FY2019 · CA · contact PI
Dysregulation of TGF Beta Action Pancreatic Cancer$441,940
R01 · FY2018 · CA · contact PI
Dysregulation of TGF Beta Action Pancreatic Cancer$3,579
R01 · FY2018 · CA · contact PI
Dysregulation of TGF Beta Action Pancreatic Cancer$441,940
R01 · FY2017 · CA · contact PI
Dysregulation of TGF Beta Action Pancreatic Cancer$49,543
R01 · FY2017 · CA · contact PI
Dysregulation of TGF Beta Action Pancreatic Cancer$441,940
R01 · FY2016 · CA · contact PI
Dysregulation of TGF Beta Action Pancreatic Cancer$58,398
R01 · FY2016 · CA · contact PI
Dysregulation of TGF Beta Action Pancreatic Cancer$441,940
R01 · FY2015 · CA · contact PI
Novel aspects of Epithelial-Mesenchymal Transition(EMT)in pancreatic cancer$54,821
R01 · FY2015 · CA · contact PI
Dysregulation of TGF Beta Action Pancreatic Cancer$441,940
R01 · FY2014 · CA · contact PI
Dysregulation of TGF Beta Action Pancreatic Cancer$400,151
R37 · FY2012 · CA · contact PI
Dysregulation of TGF Beta Action Pancreatic Cancer$417,605
R37 · FY2011 · CA · contact PI
Dysregulation of TGF Beta Action Pancreatic Cancer$452,707
R37 · FY2010 · CA · contact PI
Role of microRNAs in genetic mouse models of pancreatic cancer$139,113
R21 · FY2010 · CA · contact PI
Dysregulation of TGF Beta Action Pancreatic Cancer$462,645
R37 · FY2009 · CA · contact PI
Role of microRNAs in genetic mouse models of pancreatic cancer$243,448
R21 · FY2009 · CA · contact PI
microRNAs as novel Biomarkers for Pancreatic Ductal Adenocarcinoma$143,910
R21 · FY2009 · CA · contact PI
Dysregulation of TGF Beta Action Pancreatic Cancer$103,558
R37 · FY2009 · CA · contact PI
Dysregulation of TGF Beta Action Pancreatic Cancer$364,789
R37 · FY2008 · CA · contact PI
microRNAs as novel Biomarkers for Pancreatic Ductal Adenocarcinoma$251,843
R21 · FY2008 · CA · contact PI
Role of Glypican-1 in Pancreatic Cancer$320,862
R01 · FY2007 · CA · contact PI
Role of Neuropillins in Pancreatic Cancer$300,000
R01 · FY2007 · CA · contact PI
Dysregulation of TGF Beta Action Pancreatic Cancer$347,417
R01 · FY2006 · CA · contact PI
Role of Glypican-1 in Pancreatic Cancer$330,445
R01 · FY2006 · CA · contact PI
Role of Neuropillins in Pancreatic Cancer$308,960
R01 · FY2006 · CA · contact PI
CTSA Planning at Dartmouth Medical School$239,850
P20 · FY2006 · RR · contact PI
Dysregulation of TGF Beta Action Pancreatic Cancer$355,406
R01 · FY2005 · CA
Role of Glypican-1 in Pancreatic Cancer$338,053
R01 · FY2005 · CA
Role of Neuropillins in Pancreatic Cancer$316,395
R01 · FY2005 · CA
EPIDERMAL GROWTH FACTOR RECEPTORS AND PANCREATIC CANCER$264,950
R01 · FY2005 · CA
Dysregulation of TGF Beta Action Pancreatic Cancer$351,749
R01 · FY2004 · CA
Role of Glypican-1 in Pancreatic Cancer$351,244
R01 · FY2004 · CA
Role of Neuropillins in Pancreatic Cancer$316,395
R01 · FY2004 · CA
EPIDERMAL GROWTH FACTOR RECEPTORS AND PANCREATIC CANCER$263,248
R01 · FY2004 · CA
Role of Glypican-1 in Pancreatic Cancer$327,233
R01 · FY2003 · CA
Role of Neuropillins in Pancreatic Cancer$316,395
R01 · FY2003 · CA
EPIDERMAL GROWTH FACTOR RECEPTORS AND PANCREATIC CANCER$249,664
R01 · FY2003 · CA
Dysregulation of TGF Beta Action Pancreatic Cancer$209,148
R01 · FY2003 · CA
Dysregulation of TGF Beta Action Pancreatic Cancer$119,689
R01 · FY2003 · CA
Dysregulation of TGF Beta Action Pancreatic Cancer$326,487
R01 · FY2002 · CA
EPIDERMAL GROWTH FACTOR RECEPTORS AND PANCREATIC CANCER$249,664
R01 · FY2002 · CA
EPIDERMAL GROWTH FACTOR RECEPTORS AND PANCREATIC CANCER$267,318
R01 · FY2001 · CA
DYSREGULATION OF TGF-BETA ACTIONS IN PANCREATIC CANCER$188,039
R01 · FY2000 · CA
EPIDERMAL GROWTH FACTOR AND PANCREATIC CANCER$63,514
R01 · FY2000 · CA